Eight talks, a debate on first-line ES-SCLC and a panel on patient cases from the audience: ctDNA, targeted therapy, ADCs, early-stage IO and TCEs in SCLC, in one day. That is the International Lung Cancer Summit (ILCS) 2026, chaired by Solange Peters (@peters_solange) and Alfredo Addeo (@Alfdoc2), in Lausanne on Friday 13 November and live online. Here is the trailer. Registration is free for healthcare professionals. We would be glad to see you at CHUV, and just as glad to see you on the stream 🙂 ILCS 2026 faculty: @DasMillie11 @HHorinouchi @TelmaSequeiraMD @christine_lovly @dplanchard @PatelOncology @ACortelliniMD @g_mountzios @a_dingemans Registration is open: lungsummit.org/registration/ #ILCS2026 #LungCancer #NSCLC #SCLC

Charles Rudin (@charlesrudin) and colleagues followed DeLLphi-304 for close to 2 years, and tarlatamab kept its OS lead over chemotherapy. Among the authors is our faculty member Giannis Mountzios (@g_mountzios). 🔬 DeLLphi-304: tarlatamab vs chemotherapy, SCLC after platinum-based chemotherapy, extended follow-up 📊 mOS 13.6 vs 8.4 mo 📊 ORR 35.4% vs 20.4% ⚠️ Discontinuation for TRAEs 3.2% vs 6.6% ✅ Primary endpoint met Compare the 2-year survival estimates for each arm in our article. lungsummit.org/articles/tarl…

Renaud Descourt and colleagues report in Annals of Oncology that adding chemotherapy to pembrolizumab lengthened PFS in PD-L1-high advanced NSCLC. Among the authors is our faculty member Maurice Pérol. 🔬 PERSEE: pembrolizumab plus platinum chemotherapy vs pembrolizumab, 1L advanced NSCLC with PD-L1 50% or more 📊 mPFS 16.1 vs 6.9 mo, HR 0.56, p=<0.001 📊 mOS 50.2 vs 29.9 mo, HR 0.77 (not significant) ⚠️ Gr ≥3 TRAEs 54% vs 19% ✅ Primary endpoint met Read what the abstract leaves out on response and subgroups in our article. lungsummit.org/articles/addi…

Maurice Pérol (@MP_3855) and Jacob Sands (@sands_jacob) report in NEJM that adding tarlatamab to durvalumab maintenance lengthened OS in ES-SCLC in DeLLphi-305. Among the authors is our faculty member Anne-Marie Dingemans (@a_dingemans). 🔬 DeLLphi-305: tarlatamab plus durvalumab vs durvalumab, 1L maintenance in ES-SCLC without progression after chemoimmunotherapy 📊 mOS 21.1 vs 12.7 mo, HR 0.42, p=<0.001 (interim) 📊 mPFS 7.4 vs 1.9 mo, HR 0.34, p=<0.001 ⚠️ Gr ≥3 AEs 46.8% vs 40.6% ✅ Primary endpoint met See why the open-label design matters more for PFS than for OS in our article. @ADesaiMD lungsummit.org/articles/tarl…

Early ctDNA clearance went with longer EFS in resectable NSCLC across 3 NeoCOAST-2 arms, Tina Cascone and colleagues report in Nature. Among the authors is our faculty member Patrick Forde (@FordePatrick). 🔬 Phase 2 NeoCOAST-2 platform trial, resectable stage IIA–IIIB NSCLC, 3 additions to chemotherapy plus durvalumab 📊 ctDNA clearance at cycle 3: 50.9%, 54.5% and 72.5% with oleclumab, monalizumab and Dato-DXd 📊 Clearance vs no clearance: pooled EFS HR 0.22 (P=0.0000443) 📊 Clearance plus pCR vs neither: EFS HR 0.10 ⚠️ Exploratory association; ctDNA clearance was observed, not randomised Read in our article how the Dato-DXd arm compared on pCR. lungsummit.org/articles/earl…

A tissue biopsy is very helpful in finding transformation to SCLC, which fundamentally changes treatment at progression in EGFR-mutant NSCLC. Tom Newsom-Davis (@tnewsomdavis) tries to rebiopsy when the result will change what he does, and repeats molecular analysis on ctDNA or tissue. First-line choice, he adds, should take into account what is available second line. We recorded the interview in Zurich during the @etop_ibcsg workshop.

Thrilled to share our work in @NatureCancer! Spotting immunotherapy toxicities still relies on slow, inconsistent chart review. Our agentic AI + human review made reviewers faster, more accurate and far more consistent, at ~2¢ a note. W/ @SashaGusevPosts @EladSharonMD @DanaFarber 
nature.com/articles/s43018-0…

Experts gathered from the United States, Europe, Asia and Australia, independently of where they come from, and time given to discussion between juniors and seniors, the audience and the speakers, industry representatives and global experts. Giannis Mountzios (@g_mountzios, @HenryDunantGR) on the Summit before his third year on its faculty: “a forum to exchange ideas, to perform brainstorming”. We spoke to him at the @etop_ibcsg ADC workshop in Zurich. Next Summit 13 November 2026, CHUV Lausanne, 10 CME credits: lungsummit.org/registration/

The M2 metro from Lausanne station stops at CHUV, a short walk from the Agora building, Rue du Bugnon 25A. That is where the International Lung Cancer Summit (ILCS) 2026 meets on 13 November, from 09:45 CET, with every talk also live online. We look forward to welcoming you at the door. ILCS 2026 faculty: @peters_solange @Alfdoc2 @DasMillie11 @HHorinouchi @TelmaSequeiraMD @christine_lovly @dplanchard @PatelOncology @ACortelliniMD @g_mountzios @a_dingemans Registration is open: lungsummit.org/registration/ #ILCS2026 #LungCancer #NSCLC #SCLC

#Voting for @ASCO Election is now open. I am #honored & #humbled to be running as one of the candidates, for the #ASCO #NominatingCommittee, alongside many remarkable talented candidates & GREAT colleagues.   Visit asco.org/election to learn more about the candidates & place your vote!

HER2 and ROS1 alterations are each found in a small share of NSCLC, and both now have targeted options, but only if testing finds them first. Telma Sequeira (@TelmaSequeiraMD), of IPO Lisboa, covers them at the International Lung Cancer Summit (ILCS) 2026, in Lausanne and online on 13 November, at 10:35 CET. We hope to see you there. Registration is open: lungsummit.org/registration/ #ILCS2026 #LungCancer #NSCLC

Survival after segmentectomy for small node-negative NSCLC rose step by step with lymph node yield in 2217 SEER patients. Among the authors is our faculty member Jean Yannis Perentes. 🔬 2217 patients with clinical N0M0 NSCLC of 30 mm or less after anatomical segmentectomy, SEER 2000 to 2022 📊 5-year OS rose from 52.5% with 0 nodes examined to 83.9% with more than 10 📊 Adjusted HR for death vs 0 nodes: 0.79, 0.55 and 0.40 across rising yield groups 📊 Consistent by age and T1 subgroup; no clear plateau on spline modelling (non-linearity p=0.27) ⚠️ Retrospective registry: higher yield may reflect better staging or surgical quality, so causation is unproven Read the trials behind wider use of segmentectomy in our article. lungsummit.org/articles/more…

@DrJNaidoo, of the @CancerCentreIre in Dublin, at the recent Swiss Oncology Summer School in Gruyères, on what makes the International @LungSummit a different kind of meeting. What she picks out is the format. Key voices in thoracic oncology, an informal and dynamic setting, and a programme built on discussion, so that a listener follows the debate and feels part of the conversation. It is small enough to stay approachable and, on her account, that authenticity of discussion is something the field craves. Attendance and the online audience have both grown with it. The International @LungSummit 2026 is on Friday 13 November in Lausanne.

In first-line ES-SCLC, a new option is measured against chemo-IO on OS, and on toxicity and quality of life as well. Giannis Mountzios (@g_mountzios), of Henry Dunant Hospital Center, takes the chemo-IO side of the debate at the International Lung Cancer Summit (ILCS) 2026, in Lausanne and online on 13 November, at 16:00 CET. We would be glad to hear your questions in the room. Registration is open: lungsummit.org/registration/ #ILCS2026 #LungCancer #SCLC

TROP2-directed ADCs are in first-line phase 3 trials with IO in NSCLC, and some ADCs carry a risk of interstitial lung disease that needs monitoring throughout treatment. David Planchard (@dplanchard), of Gustave Roussy, speaks on integrating new ADCs at the International Lung Cancer Summit (ILCS) 2026, in Lausanne and online on 13 November, at 11:50 CET. We would be glad to have you with us 🙂 Registration is open: lungsummit.org/registration/ #ILCS2026 #LungCancer #NSCLC

The Swiss Oncology Summer School is organised independently of any pharmaceutical company, and @MdCurioni names that as the condition for two things at her own school: a free hand in the programme, and a free hand in the choice of speakers. The faculty comes from around the world with one scope, in her words, which is to teach. For the days it runs, the meeting is the students and the faculty and no one else.

ICIs are part of first-line treatment in extensive-stage SCLC and of consolidation in limited-stage disease. Martin Reck, of LungenClinic Grosshansdorf, opens the talks at our ESMO 2026 symposium this Sunday with what they have achieved and where they stop. We look forward to seeing you. Come and hear him in the Salamanca Auditorium, Hall 10, at 13:00. @peters_solange @MartinReck2 @g_mountzios @NReguart Add it to your calendar: lungsummit.org/calendar/sclc… Programme and faculty: lungsummit.org/featured/sclc… #ESMO26 #SCLC #LungCancer

After earlier treatment of KRAS G12C-mutant NSCLC, a newer G12C inhibitor has been tested head to head against the first ones, and Ferdinandos Skoulidis presents the phase 3 data in a Presidential session at ESMO 2026 on 25 October. Christine Lovly (@christine_lovly), of City of Hope, speaks on (K)RAS at the International Lung Cancer Summit (ILCS) 2026, in Lausanne and online on 13 November, at 11:20 CET. We hope you can be there for it 🙂 Registration is open: lungsummit.org/registration/ #ILCS2026 #LungCancer #NSCLC

ICIs, DLL3-targeted TCEs and ADCs now sit in different lines of SCLC treatment. Noemí Reguart, of Hospital Clínic de Barcelona, speaks on sequencing at our ESMO 2026 symposium this Sunday from 13:00. Come and meet her in the Salamanca Auditorium, Hall 10. We would love to see you. If your Sunday is not settled yet, the calendar link is below. @peters_solange @MartinReck2 @g_mountzios @NReguart Add it to your calendar: lungsummit.org/calendar/sclc… Programme and faculty: lungsummit.org/featured/sclc… #ESMO26 #SCLC #LungCancer